DI-002 Effectiveness and safety of δ-9-tetrahydro-cannabinol (SATIVEX) in patients with multiple sclerosis spasticity

BackgroundThe δ-9-tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray (Sativex) is a standardised cannabinoid based medicine for add on treatment of resistant multiple sclerosis (MS) induced spasticity.PurposeTo evaluate the use of oromucosal spray Sativex in terms of efficacy for symptoms a...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A113-A113
Main Authors: Guerrero, L Jiménez, Macias, I Castañeda, del Castillo, S Sandoval Fernandez, Izquierdo, M Murillo, Rengifo, C Donoso, Núñez, M Nuñez
Format: Article
Language:English
Subjects:
Multiple sclerosis
Patients
Spasticity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe δ-9-tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray (Sativex) is a standardised cannabinoid based medicine for add on treatment of resistant multiple sclerosis (MS) induced spasticity.PurposeTo evaluate the use of oromucosal spray Sativex in terms of efficacy for symptoms and functional impairment associated with resistant MS induced spasticity and safety according to type of MS.Material and methodsA retrospective cohort study was conducted in a university hospital in South Spain in patients who commenced Sativex between March 2015 and November 2015. Data were retrieved from the electronic medical records (Diraya) and the dispensing programme for outpatient (Farmatools). Patients were classified by type of MS: relapsing remitting (RR), primary progressive (PP) and secondary progressive (SP). Evaluation was performed on day 0 and day 60 of treatment with Sativex. The Modified Ashworth Scale was used for grading spasticity where ‘improvement’ was defined as >20% deviation from baseline.Results14 patients were included. 4 (28.6%) were men with a median (IQR) age of 47.5 years (37–69). Types of MS were: 10 (71.4%) RR, 1 (7.1%) PP and 3 (21.4%) SP. The overall response, defined as ‘improvement’ to Sativex, was 9 (64.3%) and by type of MS: 6/10 (60%) RR, 1/1 (100%) PP and 2/3 (66.7%) SP. Only 1 patient (7.1%) discontinued treatment due to drug related adverse events. 2 additional patient were treated with Sativex but excluded from this analysis due to a diagnose different from MS.ConclusionIn our cohort, oromucosal spray Sativex was a well tolerated drug and an effective alternative for the management of resistant MS induced spasticity. As for MS type subgroup analysis, a greater sample size is needed for more robust conclusions.No conflict of interest
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2017-000640.249